<p>RNS 编号：8655M 摩根大通 2025 年 12 月 24 日</p>
<p><strong>表格 38.5(b)</strong></p>
<p><strong>爱尔兰收购委员会</strong></p>
<p><strong>根据 1997 年爱尔兰收购委员会法第 38.5(b) 条款的披露，收购规则，2013</strong></p>
<p><strong>与没有被认可中介身份的关联豁免主要交易者的交易，或与被认可中介身份但不以客户服务身份进行交易的交易</strong></p>
<p><strong>1. 关键信息</strong></p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>豁免主要交易者名称</td>
<td>摩根大通</td>
</tr>
<tr>
<td>交易公司</td>
<td>Avadel Pharmaceuticals PLC</td>
</tr>
<tr>
<td>涉及的相关证券类别（注 1）</td>
<td>0.01 美元普通股</td>
</tr>
<tr>
<td>交易日期</td>
<td>2025 年 12 月 23 日</td>
</tr>
</tbody>
</table>
<p><strong>2. 利益和空头头寸</strong></p>
<p><strong>(a) 在所交易的相关证券类别中的利益和空头头寸（交易后）(注 2)</strong></p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>多头</td>
<td>空头</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>数量</td>
<td>(%)</td>
<td>数量</td>
<td>(%)</td>
</tr>
<tr>
<td>(1) 相关证券</td>
<td>943,558</td>
<td>(0.96)</td>
<td>486,565</td>
<td>(0.49)</td>
</tr>
<tr>
<td>(2) 衍生品（非期权）</td>
<td>39,256</td>
<td>(0.04)</td>
<td>63,843</td>
<td>(0.06)</td>
</tr>
<tr>
<td>(3) 购买/出售的期权和协议</td>
<td>0</td>
<td>(0.00)</td>
<td>0</td>
<td>(0.00)</td>
</tr>
<tr>
<td>总计</td>
<td>982,814</td>
<td>(1.00)</td>
<td>550,408</td>
<td>(0.56)</td>
</tr>
</tbody>
</table>
<p><strong>(b) 在公司相关证券中的利益和空头头寸，除了所交易的类别（注 2）</strong></p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>相关证券类别：</td>
<td>多头</td>
<td>空头</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>数量</td>
<td>(%)</td>
<td>数量</td>
<td>(%)</td>
</tr>
<tr>
<td>(1) 相关证券</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(2) 衍生品（非期权）</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(3) 购买/出售的期权和协议</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>总计</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<p>3. 交易（注 3）</p>
<p><strong>(a) 购买和销售</strong></p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>购买/销售</td>
<td>相关证券数量</td>
<td>每单位价格（注 4）</td>
</tr>
<tr>
<td>购买</td>
<td>5,451</td>
<td>21.6050 美元</td>
</tr>
<tr>
<td>购买</td>
<td>300</td>
<td>21.6150 美元</td>
</tr>
<tr>
<td>购买</td>
<td>1,162</td>
<td>21.6150 美元</td>
</tr>
<tr>
<td>购买</td>
<td>400</td>
<td>21.6150 美元</td>
</tr>
<tr>
<td>购买</td>
<td>1,232</td>
<td>21.6150 美元</td>
</tr>
<tr>
<td>购买</td>
<td>1,493</td>
<td>21.6150 美元</td>
</tr>
<tr>
<td>购买</td>
<td>381</td>
<td>21.6250 美元</td>
</tr>
<tr>
<td>购买</td>
<td>21</td>
<td>21.6350 美元</td>
</tr>
<tr>
<td>购买</td>
<td>100</td>
<td>21.6350 美元</td>
</tr>
<tr>
<td>购买</td>
<td>75</td>
<td>21.6350 美元</td>
</tr>
<tr>
<td>购买</td>
<td>188</td>
<td>21.6350 美元</td>
</tr>
<tr>
<td>购买</td>
<td>100</td>
<td>21.6350 美元</td>
</tr>
<tr>
<td>销售（新贷款）</td>
<td>1,300</td>
<td>不适用</td>
</tr>
<tr>
<td>购买（贷款全额归还）</td>
<td>1,300</td>
<td>不适用</td>
</tr>
<tr>
<td>销售（新贷款）</td>
<td>1,300</td>
<td>不适用</td>
</tr>
<tr>
<td>购买（贷款部分归还）</td>
<td>659</td>
<td>不适用</td>
</tr>
<tr>
<td>销售（新贷款）</td>
<td>690</td>
<td>不适用</td>
</tr>
<tr>
<td>购买（贷款全额归还）</td>
<td>690</td>
<td>不适用</td>
</tr>
<tr>
<td>销售（借入部分归还）</td>
<td>194,400</td>
<td>不适用</td>
</tr>
</tbody>
</table>
<p><strong>(b) 衍生品交易（非期权交易）</strong></p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>产品名称，例如 CFD</td>
<td>CFD</td>
</tr>
<tr>
<td>交易性质（注 5）</td>
<td>减少多头头寸</td>
</tr>
<tr>
<td>相关证券数量（注 6）</td>
<td>10,903</td>
</tr>
<tr>
<td>每单位价格（注 4）</td>
<td>21.5893 美元</td>
</tr>
</tbody>
</table>
<p><strong>(c) 关于现有相关证券的期权交易</strong></p>
<p><strong>(i) 写入、出售、购买或变更</strong></p>
<ul>
<li>产品名称，例如看涨期权</li>
<li>写入、出售、购买、变更等</li>
<li>与期权相关的证券数量（注 7）</li>
<li>行使价格</li>
<li>类型，例如美式、欧式等</li>
<li>到期日期</li>
<li>每单位支付/收到的期权费用（注 4）</li>
</ul>
<p><strong>(ii) 行使</strong></p>
<ul>
<li>产品名称，例如看涨期权</li>
<li>证券数量</li>
<li>每单位行使价格（注 4）</li>
</ul>
<p><strong>(d) 其他交易（包括新证券的交易）（注 3）</strong></p>
<ul>
<li>交易性质（注 7）</li>
<li>详情</li>
<li>每单位价格（如适用）（注 4）</li>
</ul>
<p><strong>4. 其他信息</strong></p>
<p><strong>与期权或衍生品相关的协议、安排或理解</strong></p>
<ul>
<li>任何披露人和其他人之间关于本表格中提到的任何期权下相关证券投票权的协议、安排或理解的完整细节，或关于本表格中提到的任何衍生品的相关证券的投票权或未来收购或处置的协议。如果没有，应予以说明。</li>
<li>无</li>
</ul>
<p>是否附有补充表格 8？（注 9）是</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>披露日期</td>
<td>2025 年 12 月 24 日</td>
</tr>
<tr>
<td>联系人姓名</td>
<td>Papa Lette 和 Andrzej Szyszka</td>
</tr>
<tr>
<td>电话号码</td>
<td>+33(1) 4212 1459 / +48(22) 317 4817</td>
</tr>
<tr>
<td>与之相关的受要约方/要约方名称</td>
<td>Avadel Pharmaceuticals PLC</td>
</tr>
<tr>
<td>关系性质（注 9）</td>
<td>受要约方顾问</td>
</tr>
</tbody>
</table>
<p><strong>补充表格 38.5(b)</strong></p>
<p><strong>爱尔兰收购委员会</strong></p>
<p><strong>根据 1997 年爱尔兰收购委员会法第 38.5(b) 条款的披露，收购规则，2013</strong></p>
<p><strong>开放头寸的详细信息</strong></p>
<p><strong>开放头寸（注 1）</strong></p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>产品名称，例如看涨期权</td>
<td>写入或购买</td>
<td>与期权或衍生品相关的相关证券数量</td>
<td>行使价格（注 2）</td>
<td>类型，例如美式、欧式等</td>
<td>到期日期</td>
</tr>
<tr>
<td>互换</td>
<td>出售</td>
<td>84</td>
<td>0.0000</td>
<td>不适用</td>
<td>2026 年 3 月 13 日</td>
</tr>
<tr>
<td>互换</td>
<td>购买</td>
<td>33,762</td>
<td>0.0000</td>
<td>不适用</td>
<td>2026 年 1 月 20 日</td>
</tr>
</tbody>
</table>
<p>注释</p>
<p>1. 如果存在开放的期权头寸或开放的衍生品头寸（除 CFD 外），应提供完整的细节。任何现有的购买或出售协议的完整细节也必须在本表格中提供。</p>
<p>2. 所有价格和其他货币金额必须注明货币。</p>
<p>有关披露要求的完整细节，请参见规则 8 和规则 38.5。如果有疑问，请咨询委员会。</p>
<p>此信息由 RNS 提供，伦敦证券交易所的新闻服务。RNS 已获得金融行为监管局的批准，作为英国的主要信息提供者。有关使用和分发此信息的条款和条件可能适用。如需更多信息，请联系 rns@lseg.com 或访问 www.rns.com。</p>
<p>RNS 可能会使用您的 IP 地址来确认您是否遵守条款和条件，分析您与本次沟通中所包含信息的互动方式，并将此分析以匿名方式与他人分享，作为我们商业服务的一部分。有关 RNS 和伦敦证券交易所如何使用您提供的个人数据的更多信息，请参阅我们的隐私政策。END ITPUSVARVOUUUAA</p>

高盛

Avadel制药

<p>高盛公司（Goldman Sachs & Co. LLC）根据 1997 年爱尔兰收购委员会法第 38.5(b) 条款披露了与 Avadel 制药（Avadel Pharmaceuticals plc）的交易情况。该披露包括对 0.01 美元普通股的权益和空头头寸、相关证券的买卖以及衍生品交易。该披露是爱尔兰收购委员会的要求，附有补充表格。高盛担任 Avadel 制药的顾问</p>

<p>RNS Number : 8655M Goldman Sachs &amp; Co. LLC 24 December 2025</p>
<div class="lb-trans"><p>RNS 编号：8655M 摩根大通 2025 年 12 月 24 日</p>
</div><p><strong>FORM 38.5(b)</strong></p>
<div class="lb-trans"><p><strong>表格 38.5(b)</strong></p>
</div><p><strong>IRISH TAKEOVER PANEL</strong></p>
<div class="lb-trans"><p><strong>爱尔兰收购委员会</strong></p>
</div><p><strong>DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013</strong></p>
<div class="lb-trans"><p><strong>根据 1997 年爱尔兰收购委员会法第 38.5(b) 条款的披露，收购规则，2013</strong></p>
</div><p><strong>DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITHOUT RECOGNISED INTERMEDIARY STATUS, OR WITH RECOGNISED INTERMEDIARY STATUS BUT NOT DEALING IN A CLIENT-SERVING CAPACITY</strong></p>
<div class="lb-trans"><p><strong>与没有被认可中介身份的关联豁免主要交易者的交易，或与被认可中介身份但不以客户服务身份进行交易的交易</strong></p>
</div><p><strong>1. KEY INFORMATION</strong></p>
<div class="lb-trans"><p><strong>1. 关键信息</strong></p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Name of exempt principal trader</td>
<td>GOLDMAN SACHS &amp; CO. LLC</td>
</tr>
<tr>
<td>Company dealt in</td>
<td>AVADEL PHARMACEUTICALS PLC</td>
</tr>
<tr>
<td>Class of relevant security to which the dealings being disclosed relate (Note1)</td>
<td>USD 0.01 ordinary shares</td>
</tr>
<tr>
<td>Date of dealing</td>
<td>23 December 2025</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>豁免主要交易者名称</td>
<td>摩根大通</td>
</tr>
<tr>
<td>交易公司</td>
<td>Avadel Pharmaceuticals PLC</td>
</tr>
<tr>
<td>涉及的相关证券类别（注 1）</td>
<td>0.01 美元普通股</td>
</tr>
<tr>
<td>交易日期</td>
<td>2025 年 12 月 23 日</td>
</tr>
</tbody>
</table>
</div><p><strong>2. INTERESTS AND SHORT POSITIONS</strong></p>
<div class="lb-trans"><p><strong>2. 利益和空头头寸</strong></p>
</div><p><strong>(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 2)</strong></p>
<div class="lb-trans"><p><strong>(a) 在所交易的相关证券类别中的利益和空头头寸（交易后）(注 2)</strong></p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Long</td>
<td>Short</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Number</td>
<td>(%)</td>
<td>Number</td>
<td>(%)</td>
</tr>
<tr>
<td>(1) Relevant securities</td>
<td>943,558</td>
<td>(0.96)</td>
<td>486,565</td>
<td>(0.49)</td>
</tr>
<tr>
<td>(2) Derivatives (other than options)</td>
<td>39,256</td>
<td>(0.04)</td>
<td>63,843</td>
<td>(0.06)</td>
</tr>
<tr>
<td>(3) Options and agreements to purchase/sell</td>
<td>0</td>
<td>(0.00)</td>
<td>0</td>
<td>(0.00)</td>
</tr>
<tr>
<td>Total</td>
<td>982,814</td>
<td>(1.00)</td>
<td>550,408</td>
<td>(0.56)</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>多头</td>
<td>空头</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>数量</td>
<td>(%)</td>
<td>数量</td>
<td>(%)</td>
</tr>
<tr>
<td>(1) 相关证券</td>
<td>943,558</td>
<td>(0.96)</td>
<td>486,565</td>
<td>(0.49)</td>
</tr>
<tr>
<td>(2) 衍生品（非期权）</td>
<td>39,256</td>
<td>(0.04)</td>
<td>63,843</td>
<td>(0.06)</td>
</tr>
<tr>
<td>(3) 购买/出售的期权和协议</td>
<td>0</td>
<td>(0.00)</td>
<td>0</td>
<td>(0.00)</td>
</tr>
<tr>
<td>总计</td>
<td>982,814</td>
<td>(1.00)</td>
<td>550,408</td>
<td>(0.56)</td>
</tr>
</tbody>
</table>
</div><p><strong>(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 2)</strong></p>
<div class="lb-trans"><p><strong>(b) 在公司相关证券中的利益和空头头寸，除了所交易的类别（注 2）</strong></p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Class of relevant security:</td>
<td>Long</td>
<td>Short</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Number</td>
<td>(%)</td>
<td>Number</td>
<td>(%)</td>
</tr>
<tr>
<td>(1) Relevant securities</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(2) Derivatives (other than options)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(3) Options and agreements to purchase/sell</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>相关证券类别：</td>
<td>多头</td>
<td>空头</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>数量</td>
<td>(%)</td>
<td>数量</td>
<td>(%)</td>
</tr>
<tr>
<td>(1) 相关证券</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(2) 衍生品（非期权）</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(3) 购买/出售的期权和协议</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>总计</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
</div><p>3. DEALINGS (Note 3)</p>
<div class="lb-trans"><p>3. 交易（注 3）</p>
</div><p><strong>(a) Purchases and sales</strong></p>
<div class="lb-trans"><p><strong>(a) 购买和销售</strong></p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Purchase/sale</td>
<td>Number of relevant securities</td>
<td>Price per unit (Note 4)</td>
</tr>
<tr>
<td>Purchase</td>
<td>5,451</td>
<td>21.6050 USD</td>
</tr>
<tr>
<td>Purchase</td>
<td>300</td>
<td>21.6150 USD</td>
</tr>
<tr>
<td>Purchase</td>
<td>1,162</td>
<td>21.6150 USD</td>
</tr>
<tr>
<td>Purchase</td>
<td>400</td>
<td>21.6150 USD</td>
</tr>
<tr>
<td>Purchase</td>
<td>1,232</td>
<td>21.6150 USD</td>
</tr>
<tr>
<td>Purchase</td>
<td>1,493</td>
<td>21.6150 USD</td>
</tr>
<tr>
<td>Purchase</td>
<td>381</td>
<td>21.6250 USD</td>
</tr>
<tr>
<td>Purchase</td>
<td>21</td>
<td>21.6350 USD</td>
</tr>
<tr>
<td>Purchase</td>
<td>100</td>
<td>21.6350 USD</td>
</tr>
<tr>
<td>Purchase</td>
<td>75</td>
<td>21.6350 USD</td>
</tr>
<tr>
<td>Purchase</td>
<td>188</td>
<td>21.6350 USD</td>
</tr>
<tr>
<td>Purchase</td>
<td>100</td>
<td>21.6350 USD</td>
</tr>
<tr>
<td>Sale (Loan New)</td>
<td>1,300</td>
<td>N/A</td>
</tr>
<tr>
<td>Purchase (Loan Full Return)</td>
<td>1,300</td>
<td>N/A</td>
</tr>
<tr>
<td>Sale (Loan New)</td>
<td>1,300</td>
<td>N/A</td>
</tr>
<tr>
<td>Purchase (Loan Partial Return)</td>
<td>659</td>
<td>N/A</td>
</tr>
<tr>
<td>Sale (Loan New)</td>
<td>690</td>
<td>N/A</td>
</tr>
<tr>
<td>Purchase (Loan Full Return)</td>
<td>690</td>
<td>N/A</td>
</tr>
<tr>
<td>Sale (Borrow Partial Return)</td>
<td>194,400</td>
<td>N/A</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>购买/销售</td>
<td>相关证券数量</td>
<td>每单位价格（注 4）</td>
</tr>
<tr>
<td>购买</td>
<td>5,451</td>
<td>21.6050 美元</td>
</tr>
<tr>
<td>购买</td>
<td>300</td>
<td>21.6150 美元</td>
</tr>
<tr>
<td>购买</td>
<td>1,162</td>
<td>21.6150 美元</td>
</tr>
<tr>
<td>购买</td>
<td>400</td>
<td>21.6150 美元</td>
</tr>
<tr>
<td>购买</td>
<td>1,232</td>
<td>21.6150 美元</td>
</tr>
<tr>
<td>购买</td>
<td>1,493</td>
<td>21.6150 美元</td>
</tr>
<tr>
<td>购买</td>
<td>381</td>
<td>21.6250 美元</td>
</tr>
<tr>
<td>购买</td>
<td>21</td>
<td>21.6350 美元</td>
</tr>
<tr>
<td>购买</td>
<td>100</td>
<td>21.6350 美元</td>
</tr>
<tr>
<td>购买</td>
<td>75</td>
<td>21.6350 美元</td>
</tr>
<tr>
<td>购买</td>
<td>188</td>
<td>21.6350 美元</td>
</tr>
<tr>
<td>购买</td>
<td>100</td>
<td>21.6350 美元</td>
</tr>
<tr>
<td>销售（新贷款）</td>
<td>1,300</td>
<td>不适用</td>
</tr>
<tr>
<td>购买（贷款全额归还）</td>
<td>1,300</td>
<td>不适用</td>
</tr>
<tr>
<td>销售（新贷款）</td>
<td>1,300</td>
<td>不适用</td>
</tr>
<tr>
<td>购买（贷款部分归还）</td>
<td>659</td>
<td>不适用</td>
</tr>
<tr>
<td>销售（新贷款）</td>
<td>690</td>
<td>不适用</td>
</tr>
<tr>
<td>购买（贷款全额归还）</td>
<td>690</td>
<td>不适用</td>
</tr>
<tr>
<td>销售（借入部分归还）</td>
<td>194,400</td>
<td>不适用</td>
</tr>
</tbody>
</table>
</div><p><strong>(b) Derivatives transactions (other than options transactions)</strong></p>
<div class="lb-trans"><p><strong>(b) 衍生品交易（非期权交易）</strong></p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Product name, e.g. CFD</td>
<td>CFD</td>
</tr>
<tr>
<td>Nature of transaction (Note 5)</td>
<td>Reducing a long position</td>
</tr>
<tr>
<td>Number of relevant securities (Note 6)</td>
<td>10,903</td>
</tr>
<tr>
<td>Price per unit (Note 4)</td>
<td>21.5893 USD</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>产品名称，例如 CFD</td>
<td>CFD</td>
</tr>
<tr>
<td>交易性质（注 5）</td>
<td>减少多头头寸</td>
</tr>
<tr>
<td>相关证券数量（注 6）</td>
<td>10,903</td>
</tr>
<tr>
<td>每单位价格（注 4）</td>
<td>21.5893 美元</td>
</tr>
</tbody>
</table>
</div><p><strong>(c) Options transactions in respect of existing relevant securities</strong></p>
<div class="lb-trans"><p><strong>(c) 关于现有相关证券的期权交易</strong></p>
</div><p><strong>(i) Writing, selling, purchasing or varying</strong></p>
<div class="lb-trans"><p><strong>(i) 写入、出售、购买或变更</strong></p>
</div><ul>
<li>Product name,e.g. call option</li>
<li>Writing, selling, purchasing, varying etc.</li>
<li>Number of securities to which the option relates (Note 7)</li>
<li>Exercise price</li>
<li>Type, e.g. American, European etc.</li>
<li>Expiry date</li>
<li>Option money paid/received per unit (Note 4)</li>
</ul>
<div class="lb-trans"><ul>
<li>产品名称，例如看涨期权</li>
<li>写入、出售、购买、变更等</li>
<li>与期权相关的证券数量（注 7）</li>
<li>行使价格</li>
<li>类型，例如美式、欧式等</li>
<li>到期日期</li>
<li>每单位支付/收到的期权费用（注 4）</li>
</ul>
</div><p><strong>(ii) Exercising</strong></p>
<div class="lb-trans"><p><strong>(ii) 行使</strong></p>
</div><ul>
<li>Product name,e.g. call option</li>
<li>Number of securities</li>
<li>Exercise price per unit (Note 4)</li>
</ul>
<div class="lb-trans"><ul>
<li>产品名称，例如看涨期权</li>
<li>证券数量</li>
<li>每单位行使价格（注 4）</li>
</ul>
</div><p><strong>(d) Other dealings (including transactions in respect of new securities) (Note 3)</strong></p>
<div class="lb-trans"><p><strong>(d) 其他交易（包括新证券的交易）（注 3）</strong></p>
</div><ul>
<li>Nature of transaction (Note 7)</li>
<li>Details</li>
<li>Price per unit (if applicable) (Note 4)</li>
</ul>
<div class="lb-trans"><ul>
<li>交易性质（注 7）</li>
<li>详情</li>
<li>每单位价格（如适用）（注 4）</li>
</ul>
</div><p><strong>4. OTHER INFORMATION</strong></p>
<div class="lb-trans"><p><strong>4. 其他信息</strong></p>
</div><p><strong>Agreements, arrangements or understandings relating to options or derivatives</strong></p>
<div class="lb-trans"><p><strong>与期权或衍生品相关的协议、安排或理解</strong></p>
</div><ul>
<li>Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.</li>
<li>NONE</li>
</ul>
<div class="lb-trans"><ul>
<li>任何披露人和其他人之间关于本表格中提到的任何期权下相关证券投票权的协议、安排或理解的完整细节，或关于本表格中提到的任何衍生品的相关证券的投票权或未来收购或处置的协议。如果没有，应予以说明。</li>
<li>无</li>
</ul>
</div><p>Is a Supplemental Form 8 attached? (Note 9) YES</p>
<div class="lb-trans"><p>是否附有补充表格 8？（注 9）是</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Date of disclosure</td>
<td>24 December 2025</td>
</tr>
<tr>
<td>Contact name</td>
<td>Papa Lette and Andrzej Szyszka</td>
</tr>
<tr>
<td>Telephone number</td>
<td>+33(1) 4212 1459 / +48(22) 317 4817</td>
</tr>
<tr>
<td>Name of offeree/offeror with which connected</td>
<td>AVADEL PHARMACEUTICALS PLC</td>
</tr>
<tr>
<td>Nature of connection (Note 9)</td>
<td>Advisor to Offeree</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>披露日期</td>
<td>2025 年 12 月 24 日</td>
</tr>
<tr>
<td>联系人姓名</td>
<td>Papa Lette 和 Andrzej Szyszka</td>
</tr>
<tr>
<td>电话号码</td>
<td>+33(1) 4212 1459 / +48(22) 317 4817</td>
</tr>
<tr>
<td>与之相关的受要约方/要约方名称</td>
<td>Avadel Pharmaceuticals PLC</td>
</tr>
<tr>
<td>关系性质（注 9）</td>
<td>受要约方顾问</td>
</tr>
</tbody>
</table>
</div><p><strong>SUPPLEMENTAL FORM 38.5(b)</strong></p>
<div class="lb-trans"><p><strong>补充表格 38.5(b)</strong></p>
</div><p><strong>IRISH TAKEOVER PANEL</strong></p>
<div class="lb-trans"><p><strong>爱尔兰收购委员会</strong></p>
</div><p><strong>DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013</strong></p>
<div class="lb-trans"><p><strong>根据 1997 年爱尔兰收购委员会法第 38.5(b) 条款的披露，收购规则，2013</strong></p>
</div><p><strong>DETAILS OF OPEN POSITIONS</strong></p>
<div class="lb-trans"><p><strong>开放头寸的详细信息</strong></p>
</div><p><strong>OPEN POSITIONS (Note 1)</strong></p>
<div class="lb-trans"><p><strong>开放头寸（注 1）</strong></p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Product name,e.g. call option</td>
<td>Written or purchased</td>
<td>Number of relevant securities to which the option or derivative relates</td>
<td>Exercise price (Note 2)</td>
<td>Type, e.g. American, European etc.</td>
<td>Expiry date</td>
</tr>
<tr>
<td>Swap</td>
<td>Sold</td>
<td>84</td>
<td>0.0000</td>
<td>N/A</td>
<td>13/03/2026</td>
</tr>
<tr>
<td>Swap</td>
<td>Purchased</td>
<td>33,762</td>
<td>0.0000</td>
<td>N/A</td>
<td>20/01/2026</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>产品名称，例如看涨期权</td>
<td>写入或购买</td>
<td>与期权或衍生品相关的相关证券数量</td>
<td>行使价格（注 2）</td>
<td>类型，例如美式、欧式等</td>
<td>到期日期</td>
</tr>
<tr>
<td>互换</td>
<td>出售</td>
<td>84</td>
<td>0.0000</td>
<td>不适用</td>
<td>2026 年 3 月 13 日</td>
</tr>
<tr>
<td>互换</td>
<td>购买</td>
<td>33,762</td>
<td>0.0000</td>
<td>不适用</td>
<td>2026 年 1 月 20 日</td>
</tr>
</tbody>
</table>
</div><p>Notes</p>
<div class="lb-trans"><p>注释</p>
</div><p>1. Where there are open option positions or open derivative positions (except for CFDs), full details should be given. Full details of any existing agreements to purchase or to sell must also be given on this form.</p>
<div class="lb-trans"><p>1. 如果存在开放的期权头寸或开放的衍生品头寸（除 CFD 外），应提供完整的细节。任何现有的购买或出售协议的完整细节也必须在本表格中提供。</p>
</div><p>2. For all prices and other monetary amounts, the currency must be stated.</p>
<div class="lb-trans"><p>2. 所有价格和其他货币金额必须注明货币。</p>
</div><p>For full details of disclosure requirements, see Rules 8 and 38.5 of the Rules. If in doubt, consult the Panel.</p>
<div class="lb-trans"><p>有关披露要求的完整细节，请参见规则 8 和规则 38.5。如果有疑问，请咨询委员会。</p>
</div><p>This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.</p>
<div class="lb-trans"><p>此信息由 RNS 提供，伦敦证券交易所的新闻服务。RNS 已获得金融行为监管局的批准，作为英国的主要信息提供者。有关使用和分发此信息的条款和条件可能适用。如需更多信息，请联系 rns@lseg.com 或访问 www.rns.com。</p>
</div><p>RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END ITPUSVARVOUUUAA</p>
<div class="lb-trans"><p>RNS 可能会使用您的 IP 地址来确认您是否遵守条款和条件，分析您与本次沟通中所包含信息的互动方式，并将此分析以匿名方式与他人分享，作为我们商业服务的一部分。有关 RNS 和伦敦证券交易所如何使用您提供的个人数据的更多信息，请参阅我们的隐私政策。END ITPUSVARVOUUUAA</p>
</div>

REG - 高盛 & Co. Avadel 制药公司 - 38.5b-Avadel 制药公司